Dr. Gregory F. Egnaczyk, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 845
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
OH license 35096425 -
Cardiovascular Disease Physician
OH license 35.096425
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Miami Valley Hospital Dayton, OH
- Christ Hospital Cincinnati, OH
- Kettering Health Main Campus Kettering, OH
- Mercy Health - Clermont Hospital Batavia, OH
- Margaret Mary Community Hospital Inc Batesville, IN
Medical groups
- Kettering Independent Medical Group Inc (710 clinicians)
- Premier Health Specialists Inc (580 clinicians)
- The Christ Hospital Cardiovascular Associates LLC (152 clinicians)
- Vh Provider Group PA (9 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 845
- Services billed
- 2,179
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 481 | 317 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 266 | 264 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 221 | 66 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 204 | 73 |
| Evaluation of lower heart chamber assist device | 133 | 32 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 125 | 105 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 108 | 106 |
| Ultrasound of heart, follow-up | 98 | 76 |
| Heart muscle strain imaging | 73 | 72 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 72 | 59 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Entresto (sacubitril/valsartan) Other prescribers in Cincinnati, OH | 978 |
| Bisoprolol Fumarate Other prescribers in Cincinnati, OH | 710 |
| Atorvastatin Calcium Other prescribers in Cincinnati, OH | 654 |
| Spironolactone Other prescribers in Cincinnati, OH | 643 |
| Metoprolol Succinate Other prescribers in Cincinnati, OH | 536 |
| Torsemide Other prescribers in Cincinnati, OH | 456 |
| Eliquis (apixaban) Other prescribers in Cincinnati, OH | 439 |
| Jardiance (empagliflozin) Other prescribers in Cincinnati, OH | 410 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Cincinnati, OH | 334 |
| Furosemide Other prescribers in Cincinnati, OH | 226 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 20 payments worth $862 in total to this clinician.
| Abbott Laboratories | $288 |
|---|---|
| Briohealth Solutions, Inc. | $148 |
| Cvrx, Inc. | $105 |
| Genzyme Corporation | $104 |
| Bayer HealthCare Pharmaceuticals Inc. | $46.00 |
| AstraZeneca Pharmaceuticals LP | $44.03 |
| Kestra Medical Technology Services, Inc. | $43.37 |
| Novo Nordisk Inc | $35.71 |
| Food and Beverage | $862 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $500 in research payments for these studies, mostly to the institutions running them.
- PSR-MCS
Medtronic, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.